Home Blog Page 2647

LifeTech Scientific Corporation Announces 2025 Interim Results: Core Business Demonstrated Resilience, Domestic and Overseas Sales Both Increased

By
Advertorial Desk
-

HONG KONG, Aug. 30, 2025 /PRNewswire/ — LifeTech Scientific Corporation (“LifeTech” or the “Company”, together with its subsidiaries, the “Group”, stock code: 1302.HK), a medical device company specializing in minimally invasive interventional solutions for cardio-cerebrovascular and peripheral vascular diseases, today announced its unaudited consolidated results for the six months ended 30 June 2025 (the “Reporting Period”).

Revenue Growth: The Group achieved revenue of approximately RMB676.7 million during the Reporting Period, representing a year-on-year increase of approximately 3.7%.

Stable Profitability: Gross profit was approximately RMB497.8 million. Excluding certain non-recurring items[1], net profit attributable to owners of the Company was approximately RMB238.5 million, representing a year-on-year increase of approximately 2.1%.

Strong Cash Position: As at 30 June 2025, the Group’s cash and cash equivalents amounted to approximately RMB782.6 million, representing an increase of approximately 17.5% compared with 31 December 2024.

Note [1]: Such non-recurring items include (i) the other gains arising from financial assets at fair value through profit or loss (“FVTPL”); and (ii) the share-based payment expenses.

Increase in Both Domestic and Overseas Sales

In the first half of 2025, the Group continued to implement a proactive and prudent development strategy, with a strong focus on addressing unmet clinical needs worldwide. By leveraging its synergies in branding, intellectual property, distribution, clinical registration, and global operations, the Group strengthened its long-term growth fundamentals and achieved sales growth in both domestic and overseas markets, driven by an expanding portfolio of innovative products and professional academic services.

China’s mainland remained the foundation and largest market of the Group, where the sales generated accounted for approximately 74.1% of the total revenue of the Group during the Reporting Period. The Group continued to deepen its presence in the mainland China market, achieving a sales increase of approximately 2.2% year-on-year in the first half of 2025.

Meanwhile, overseas business maintained its upward momentum. Benefiting from proactive expansion and effective marketing strategies, the Group’s overseas sales grew by approximately 8.0% year-on-year. Asia (excluding China’s mainland) and Europe were the two largest overseas markets of the Group, where the sales generated accounted for approximately 11.4% and 11.0%, respectively, of the total revenue.

Core Business Demonstrated Resilience

The Group currently has three main product lines, covering the Structural Heart Diseases (SHD) business, the Peripheral Vascular Diseases (PVD) business and the Cardiac Pacing and Electrophysiology (CPE) business.

The revenue of the Group was approximately RMB676.7 million during the Reporting Period, representing a year-on-year growth of approximately 3.7%. The revenue increase was primarily driven by the sales increase of stent grafts and left atrial appendage (LAA) occluders, which rose by approximately 9.6% and 14.7% year-on-year, respectively.

SHD Business
The Group has established a diversified product portfolio in the SHD business, mainly including LAA occluders and three generations of congenital heart diseases occluders, aiming to address various market demands through differentiated product strategies.

During the Reporting Period, the sales contributed by the SHD business were approximately RMB271.5 million, representing a year-on-year increase of approximately 0.1%. Continuous technological innovation and product upgrades will further enrich the Group’s SHD product portfolio and enhance its global sales layout.

PVD Business
The Group is committed to providing patients worldwide with technology-leading systematic and comprehensive interventional medical devices solutions of PVD. The products offered by the Group in the PVD business mainly include vena cava filters, thoracic aortic stent grafts, abdominal aortic stent grafts, iliac artery bifurcation stent grafts, aortic stent graft systems and aortic arch stent graft systems.

During the Reporting Period, the sales contributed by the PVD business were approximately RMB391.7 million, representing a year-on-year growth of approximately 2.9%.

CPE Business
The Company is the first manufacturer in China that has a complete product portfolio of domestic implantable cardiac pacemakers with international-level technology and functions.

During the Reporting Period, the sales contributed by the CPE business were approximately RMB13.5 million, representing a significant year-on-year growth of approximately 1,400.0%.

R&D and Commercialization Progress

The Group is committed to independent innovation, aiming to provide medical devices that deliver exceptional clinical value to physicians and patients while enhancing its long-term competitiveness.

In the first half of 2025, the R&D investment (including capitalized expenditure) of the Group amounted to approximately RMB156.0 million, leading to the following key milestones:

  • Aortic Stent Graft System (consists of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System), Aortic Arch Stent Graft System (consists of the Ankura™ Plus Aortic Arch Stent Graft System and CSkirt™ Aortic Arch Branch Stent Graft System), Peripheral Balloon Dilatation Catheter (Large diameter), Yoscop™ Multi-loop Snare System and SteerEase™-m Introducer have obtained the National Medical Products Administration (“NMPA”) certification;
  • IrisFit™ PFO Occluder and SteerEase™ Introducer have obtained the CE MDR (Medical Device Regulation) certification. Such products have previously obtained the CE MDD (Medical Device Directive) certification;
  • Thoracoabdominal Artery Stent Graft System (consists of the G-Branch™ Thoracoabdominal Aortic Stent Graft System, SilverFlow™ PV Peripheral Vascular Stent Graft System and Aortic Extension Stent Graft System) and Iliac Bifurcation Device (consists of the G-iliac™ Pro Iliac Bifurcation Stent Graft System and SilverFlow™ Pro Internal Iliac Stent Graft System), etc. are pending registration approval in China;
  • Aortic Stent Graft System (consists of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System), Fitaya™ Vena Cava Filter System, Futhrough™ Stent Graft Balloon Catheter, Yuranos™ Abdominal Aortic Stent Graft System and G-iliac™ Iliac Bifurcation Device are pending registration approval of CE certification;
  • Concave Supra-arch Branched Stent-Graft System, X-Clip™ Mitral Valve Clip System and Aortic Arch Single Branch Stent Graft System (consists of the Aortic Arch Stent Graft System and Aortic Branch Stent Graft System) are currently at the stage of pre-registration clinical enrollment in China;
  • Cera™ PFO Occluder has completed pre-marketing clinical enrollment and is currently under clinical follow-up in China;
  • IBS Titan™ Sirolimus-Eluting Iron Bioresorbable Peripheral Scaffold System is currently at the stage of clinical enrollment in China and in Europe, and its CE registration application has been submitted; and
  • IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System has successfully completed the five-year follow-up of the phase I clinical study and the two-year follow-up of the phase II and III clinical study, further confirming its safety and efficacy. Additionally, its CE and NMPA registration application have been submitted.

Intellectual Property Rights

Intellectual property is an internal driving force to improve our core competitiveness in the medical device market. As at 30 June 2025, the Group had filed a total of 2,464 valid patent applications worldwide, of which 1,123 patents had been granted.

Strategic Collaboration to Enter Electrophysiology Market

On 6 June 2025, the Company, through its wholly-owned subsidiary LifeTech Shenzhen, entered into a series of agreements to invest RMB150.0 million in Affector Medtech (Suzhou) Ltd., (“Affector Medtech”), a high-tech company specializing in electrophysiology and innovative medical devices.

The investment will be carried out in stages, subject to the achievement of certain milestones as set out in the investment agreement. As at the date of the Group’s 2025 interim results announcement, the first stage of the investment has been completed, and Lifetech Shenzhen has acquired a 22.22% equity interest in Affector Medtech. After completion of all stages of the investment, Lifetech Shenzhen will be entitled to 30% of the equity interest in Affector Medtech.

The two parties will focus on the research, development, and commercialization of innovative products and advanced technologies in the field of cardiac electrophysiology, accelerating global breakthroughs in domestically innovated products in cardiac electrophysiology.

The Chairman and CEO of LifeTech, Mr. XIE Yuehui Said:

In the first half of 2025, through our continuous efforts in R&D, channel expansion, production quality control, and internal management, our market foundation has been further strengthened, our globalization process has deepened, and the clinical translation of our product R&D has achieved milestones, demonstrating our strong business resilience. At the same time, the strategic investment in Affector Medtech has opened up vast opportunities in the high-growth electrophysiology market, which will further expand our growth potential with significant synergistic effects.

Guided by our two core development strategies of “innovation” and “internationalization”, we will continuously stimulate our business vitality in the global market and accelerate product development alongside the clinical application of new technologies to benefit more patients worldwide. Leveraging our strong technological capabilities and differentiated portfolio of innovative products, we are poised to capture a larger global market share and further solidify our industry leadership.

Meanwhile, we will strategically position ourselves to capture new growth opportunities worldwide, continuously enhance our resource integration capabilities, strengthen internal and external collaboration, and maintain a prudent yet efficient business operation and capital allocation strategy to advance the company toward higher-quality sustainable development and create long-term value for patients, healthcare providers, shareholders, and all other stakeholders.

About LifeTech Scientific Corporation

Established in 1999 in Shenzhen, China, LifeTech Scientific Corporation (Stock Code: 1302.HK) specializes in the R&D, manufacturing, and sales of minimally invasive interventional medical devices for the treatment of cardio-cerebrovascular and peripheral vascular diseases. The Company offers innovative solutions for structural heart diseases, peripheral vascular diseases, bradycardia, and neurovascular conditions. It also possesses the world’s first innovative iron-based bioabsorbable material technology platform.

Guided by the core strategy of “innovation” and “internationalization”, LifeTech maintains a leading market position for its key products in the home country and has established 7 subsidiaries overseas, extending its sales network to nearly 120 countries and regions worldwide.

 

Jacobio Pharma Announces 2025 Interim Results

By
Advertorial Desk
-

BEIJING and SHANGHAI and BOSTON, Aug. 30, 2025 /PRNewswire/ — Jacobio Pharma (1167.HK) today announced its interim results for the six months ended June 30, 2025.

During the reporting period, the Company achieved revenue of RMB45.7 million, representing a 100% increase compared with the same period in 2024. Research and development (R&D) expenses amounted to  RMB93.2 million. The net loss for the first half of 2025 was RMB59.0 million,  narrowing by 65.1% compared with the same period in 2024. As of June 30, 2025, Jacobio maintained cash and bank balances, and investments in capital protected structure deposits, totaling RMB1,07billion, along with RMB270 million bank credit available which provides sufficient and stable liquidity to support our R&D activities.

Dr. Yinxiang Wang, Chairman and Chief Executive Officer of Jacobio, said: “In the first half of 2025, we reached an important milestone with the  approval and launch of Glecirasib in China. Through our collaboration with business partners, we significantly alleviated the pressure of R&D investment, enabling the Company to focus resources on advancing our pan-KRAS inhibitor and ADC pipeline. Looking forward, we  remain committed  to a transformative innovation  strategy, working hand in hand with global partners to accelerate the development of breakthrough therapies and deliver benefits to more cancer patients.”

Accelerated Progress in Core Programs

JAB-23E73 (pan-KRAS inhibitor):

  • The dose-escalation portion of the phase I trials are onging in China and the U.S, respectively.
  • Safety profile: low incidence of skin toxicity (rash observed in 10%, all Grade 1) no Grade ≥3 liver toxicity reported to date.
  • Favorable PK with predicted exposure.
  • Multiple partial responses have been observed to date.
  • Preclinical data to be presented at the AACR-NCI-EORTC International Conference in October 2025.
  • Phase I results readout expected in the first half of 2026.

JAB-BX600 (First-in-class EGFR-KRAS G12Di ADC):

  • This program uses a highly potent KRAS G12D inhibitor as the payload.
  • The candidate demonstrates picomolar (pM)-level cellular activity, compared with nanomolar (nM) typically achieved by oral small molecules.
  • Unlike oral small molecules usually achieve tumor drug concentrations 1–10x higher than plasma levels, the JAB-BX 600 delivers a KRAS G12D inhibitor at 1,000 x higher in tumor, resulting in a substantially wider therapeutic window.
  • The KRAS G12D inhibitor and EGFR antibody have synergistic effect and durable anti-tumor activity.
  • IND submission planned for the second half of 2026.

Glecirasib (JAB-21822, KRAS G12C inhibitor):

  • Approved by China’s NMPA in May 2025 for ≥2L KRAS G12C mutant NSCLC, successfully launched in China.
  • Triggered a RMB50 million milestone payment in addition to the RMB200 million upfront received in 2024.
  • The full second-line NSCLC dataset has been published in Nature Medicine (Impact Factor: 50).
  • Phase I/II data for the combination with SHP2 inhibitor has been accepted by a top-tier academic journal, with publication expected in H2 2025.

Sitneprotafib (JAB-3312, SHP2 inhibitor):

  • Ongoing Phase III registration trial in combination with Glecirasib as first-line NSCLC treatment in China.
  • Translational research published in Clinical Cancer Research (Impact Factor: 10.2), demonstrating significant synergy with Glecirasib.

JAB-BX467 (HER2-STING iADC):

  • A HER2-targeted ADC carrying a STING agonist, designed to convert “cold tumors” into “hot tumors” and address the 70% of patients unresponsive to PD-1 inhibitors.
  • Currently in IND-enabling stage, with IND filing planned for H2 2026.

 

Ingdan, Inc. (400.HK) Announces 2025 Interim Results

By
Advertorial Desk
-

Highlights of the Interim Results for the Six Months Ended June 30, 2025:

  • Benefiting from the sustained growth in AI computing power demand, the demand for chips has grown significantly across related industries, driving the Group’s revenue up by approximately 54.5% year-on-year to RMB6,676.5 million.
  • The Group recorded a gross profit of approximately RMB585.9 million, and a net profit of approximately RMB190.0 million. Profit attributable to equity shareholders of the Company was approximately RMB132.1 million, representing an increase of approximately 17.2% year-on-year.
  • Through deep collaboration with Huawei, and leveraging the Ascend 910 chip, Ingdan launched the DeepSeek all-in-one workstation to address the core computing power needs of scientific researchers. Ingdan simultaneously maintained strategic focus on two-wheeler battery cloud services, promoting business diversification.

HONG KONG SAR – Media OutReach Newswire – 29 August 2025 – Ingdan, Inc. (“Ingdan, Inc.” or the “Company”, stock code: 400.HK; with its subsidiaries (the “Group”)) – an application solution platform based upon artificial intelligence (“AI”) chips, with its core businesses “Comtech” and “Ingdan” – announces its unaudited interim results for the six months ended June 30, 2025 (the “First Half of 2025” or the “Period”).

Financial Highlights for the First Half of 2025

During the Period, benefiting from continued strong demand for AI computing power and growing demand for chips from industries related to AI technology, the Group recorded revenue of approximately RMB6,676.5 million, representing an increase of approximately 54.5% as compared to approximately RMB4,321.4 million for the corresponding period in 2024. Gross profit was approximately RMB585.9 million, representing an increase of approximately 28.0% year-on-year, primarily due to the increase in revenue. Profit from operations was approximately RMB275.6 million, representing an increase of approximately 20.8% year-on-year. Profit attributable to equity shareholders of the Company was approximately RMB132.1 million, a year-on-year growth of 17.2%.

As of June 30, 2025, the Company’s cash and bank balances (including pledged deposits) totalled approximately RMB1,626.8 million; bank loans were RMB2,561.2 million; the inventory value was RMB4,877.3 million; the number of basic ordinary shares issued by the Group was 1,644,262,732, and the weighted average number of ordinary shares of diluted earnings per share was 1,544,335,000.

Business Review

During the Period, with deep insights into chip characteristics upstream and industry needs downstream, the Group developed mature application solutions for frontier sectors such as robotics, auto pilot, and the low-altitude economy, helping customers lower their technical barriers and accelerating product innovation. The Group created additional value from “chip selection” to “chip application”, providing “ready-to-use” core technology modules. The modules have significantly shortened customers’ R&D cycles, allowing them to focus on the differentiated innovation of their applications, and to capture early opportunities in the market. Meanwhile, the Group deeply integrated AI technology into its internal operations, achieving intelligent upgrades across our core business processes from marketing and customer acquisition, to supply chain management, which has so far effectively improved operational efficiency.

In terms of the business model, the Group has established a unique closed-loop business model and accomplished a strategic evolution from “chip selling” to “technology integration”. The Group provides customers with efficient supply chain services, in-depth technical solutions, and customized products.

The Group leverages its industry ecosystem to integrate transaction data from all resources, including chips, software, and professional services, empowering the entire value chain both upstream and downstream. Additionally, the Group is providing customized solutions to downstream clients, while providing market demand data to upstream chip suppliers, forming a highly efficient and unique closed-loop business model. This model effectively strengthens our customer loyalty and builds a solid competitive barrier, making it a core driver of the Group’s sustainable development.

Comtech: Advancing AI Computing Power Supply Chain, Comtech Drive Innovation and Operational Excellence

As a core supplier in the AI computing power supply chain, Comtech serves a broad spectrum of sectors, including computing centers, data centers, AI servers, AI switch networking products, optical modules and a wide range of AI applications. Comtech works closely with global leading chip manufacturers and has been an agent for the products of over 80 core chip companies, including Nvidia, Xilinx, Intel, AMD, ST, and other well-known international manufacturers, as well as numerous domestic chip makers.

With years of successful business operations, Comtech has accumulated extensive application technology experience and industrial resources, enabling it to provide chip application technology solutions and supply chain management services to tens of thousands of customers downstream of the innovation industry. At the same time, with the help of proprietary AI technology, LLMs, and professional knowledge bases, Comtech is providing intelligent and automated solutions in the areas of chip selection, hardware design, software development, and system integration. By utilizing AI technology and big data analysis, Comtech has achieved intelligent management of the supply chain, significantly enhanced operational efficiency while reduced costs. Additionally, Comtech holds a number of proprietary intellectual properties, giving it a competitive advantage in the fields of AI chip application and intelligent supply chain.

In addition, the Group has applied to the Shenzhen Bureau of the China Securities Regulatory Commission for pre-listing guidance regarding the proposed spin-off and proposed A-share listing of Comtech. The application has been accepted on the record. Upon completion of the Proposed Spin-off and Proposed A-share Listing, the Group will remain the ultimate controlling shareholder of Comtech, and its results will continue to be consolidated into the Group, being expected to generate long-term growth for the Group’s business.

Ingdan: Targeting the New Energy Industry, Ingdan Academy Empowers the Chip Industry with AI and Digital Solutions

Bolstered by supportive national policies, the scientific research sector has increasing need for domestic computing power. Ingdan has seized the opportunity, and expanded its presence by providing high-performance adaptable hardware and dedicated domestic solutions, along with comprehensive, lifecycle technical maintenance. Ingdan has also integrated “hardware + software + service” into a closed-loop, one-stop service that fully meets our customers’ needs. Meanwhile, through deep collaboration with Huawei and leveraging the Ascend 910 chip, Ingdan launched the DeepSeek all-in-one workstation to address the core computing power needs of scientific researchers. With the growth of Huawei’s Ascend ecosystem, Ingdan will increase its focus on scientific research customers to quickly capture market opportunities in the short term; then leverage this foundation to expand into the broader enterprise market mid-term; and finally, achieve sustainable business growth through deep integration into the industry chain via joint R&D long-term.

Ingdan also focuses on the new energy industry, dedicating efforts to developing the industry for two-wheeler battery replacement and re-utilization, as well as building a reliable asset management platform for traceable lithium battery life-cycle data. Ingdan provides customized solutions for two-wheeler battery replacement, power re-utilization, and energy storage. Ingdan has strategically focused on two-wheeler battery cloud services, aiming to capture the market trend of new energy smart battery clouds. This supports the Group in achieving sustainable profit growth and contributing to advancing product standardisation in China’s two-wheeler battery-swapping industry.

Based on the Group’s resources and technological strengths in the chip industry, Ingdan Academy provides technical services and talent training for the industry. Through technical training, Ingdan Academy assisted upstream AI chip manufacturers in promoting their products and technologies in the market, while growing AI technical talents to help downstream AI application companies to swiftly adopt the latest AI technologies and products, and enhance enterprises’ AI capabilities. Furthermore, Ingdan Academy provides enterprises with locally deployed AI LLM application solutions, and helps enterprises achieve multidisciplinary AI digital transformations. To date, Ingdan Academy has successfully trained over 8,000 chip application engineers. Through talent training and technical support, Ingdan Academy will support Shenzhen as it becomes a leading chip application industry hub in China and globally, making a greater contribution to the development of the national chip industry.

Future Prospects

Mr. Jeffrey Kang, CEO of Ingdan, Inc., said, “During the Period, we successfully completed our strategic upgrade from a chip trading platform to a technology integration platform, underpinned by robust performance. During this transition, we established an efficient ‘customer acquisition-engagement-conversion’ business closed-loop, enabling us to serve tens of thousands of innovative enterprises. Our core competitiveness has evolved beyond the confines of a single business, demonstrating the synergistic strengths of our entire system. Moving forward, we will continue to leverage ‘infrastructure + value-added services’ as our dual engines, transforming data resources into strategic assets. This will further solidify our competitive moat as we progressively become a leading technology service platform for global innovative enterprises, generating long-term and sustainable value for our shareholders.”

Caution Statement

The information contained in this document has not been independently verified. No representation, warranty or undertaking, express or implied, is made by the Company or any of its affiliates, advisers or representatives as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of such information, or opinions presented or contained herein. The information contained in this document should be considered in the context of the circumstances prevailing at the time, is subject to change without notice and the Company makes no undertaking to update the information in this document to reflect any developments that occur after the date of the presentation. It is not the Company’s intention to provide, and you may not rely on these materials as providing, a complete or comprehensive analysis of the Company, or its financial or trading position or prospects. Neither of the Company nor any of its affiliates, advisers or representatives accept any responsibility or have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document.

This document may contain statements that reflect the Company’s current intent, beliefs, and expectations about the future as of the respective dates indicated herein. These forward-looking statements do not guarantee future performance and are based on a number of assumptions about the Company’s operations and factors beyond the Company’s control and are subject to significant risks and uncertainties, and accordingly, actual results may differ materially from those described in these forward-looking statements. Neither the Company nor any of its affiliates, advisers or representatives has any obligation, nor do they undertake, to update these forward-looking statements for any events or developments including the occurrence of unanticipated events that occur subsequent to such dates.

– End –

About Ingdan, Inc.

Ingdan, Inc. (stock code: 400.HK) is an innovative technology services platform conglomerate, connecting upstream chip technology with the needs of downstream innovation enterprises. Through proprietary artificial intelligence (AI) technology, large language models (“LLMs”), and specialized industry knowledge bases, the Group provides our customers with the cutting-edge of chip application technology solutions, and efficient supply chain management services. Headquartered in Shenzhen, with offices and branches across major cities in China, including Hong Kong, Shanghai, Beijing, Wuhan, Chengdu, Nanjing, Hangzhou, and Xi’an, as well as overseas branches in Singapore and Japan. The Group’s core businesses are Comtech (“Comtech”), a technology services platform for the chip industry, and Ingdan (“Ingdan”), a platform providing Artificial Intelligence of Things (AIoT) technology and services.

For further information, please refer to the Company’s website at www.ingdangroup.com
Hashtag: #Ingdan

The issuer is solely responsible for the content of this announcement.

/C O R R E C T I O N — METALTECH & AUTOMEX/

By
Advertorial Desk
-

In the news release, AUTOMEX PENANG 2025 LAUNCHES, PIVOTING MALAYSIA’S MANUFACTURING SECTOR TOWARD INDUSTRY 4.0 LEADERSHIP, issued 28-Aug-2025 by METALTECH & AUTOMEX over PR Newswire, we are advised by the company that the 9th paragraph, 2nd sentence, should read “The press conference was attended by YB Jagdeep Singh Deo, Penang Deputy Chief Minister II, Dato’ Seri Wong Siew Hai, President, Malaysia Semiconductor Industry Association (MSIA), Ir. Johnson Tan, President, Malaysia Automation Technology Association (MATA), Geonice Chong, Deputy Event Director of AUTOMEX Penang and representatives from the Penang Convention & Exhibition Bureau (PCEB).” rather than “The press conference was attended by YB Jagdeep Singh Deo, Penang Deputy Chief Minister II, Andrew Chan, Executive Director, Malaysia Semiconductor Industry Association (MSIA), Ir. Johnson Tan, President, Malaysia Automation Technology Association (MATA), Geonice Chong, Deputy Event Director of AUTOMEX Penang and representatives from the Penang Convention & Exhibition Bureau (PCEB).” as originally issued inadvertently. The complete, corrected release follows:

AUTOMEX PENANG 2025 LAUNCHES, PIVOTING MALAYSIA’S MANUFACTURING SECTOR TOWARD INDUSTRY 4.0 LEADERSHIP

Penang’s “Silicon Valley of the East” to Host Premier Automation and Semiconductor Showcase, Driving Advanced Manufacturing and Global Supply Chain Integration

GEORGE TOWN, Malaysia, Aug. 28, 2025 /PRNewswire/ — AUTOMEX, Malaysia’s leading exhibition for automation and manufacturing technology, is set to make its highly anticipated debut in Penang from 4–6 November 2025 at the Setia SPICE Convention Centre.  The strategic expansion marks a major milestone for AUTOMEX. Building on its 14-year co-location with METALTECH in Kuala Lumpur and nearly three decades of driving industrial innovation nationwide, AUTOMEX is now bringing its focus to Penang – one of Southeast Asia’s most vital industrial corridors.

AUTOMEX Penang Press Conference held at KOMTAR with a special appearance by Penang Deputy Chief Minister II, YB Jagdeep Singh Deo
AUTOMEX Penang Press Conference held at KOMTAR with a special appearance by Penang Deputy Chief Minister II, YB Jagdeep Singh Deo

Recognised globally as the “Silicon Valley of the East,” Penang is home to a powerhouse ecosystem of over 300 multinational corporations and thousands of SMEs. AUTOMEX Penang will directly serve this northern manufacturing hub, showcasing the future of industrial innovation and solidifying Malaysia’s position in the global supply chain.

The inaugural event is expected to feature over 300 exhibitors and attract more than 5,000 trade visitors, offering a dynamic platform for forging partnerships, accelerating technology adoption, and driving economic growth.

AUTOMEX Penang 2025 will showcase breakthrough technologies in automation, next-generation robotics, artificial intelligence, Internet of Things (IoT) solutions, precision CNC machinery, and sustainable manufacturing. The exhibition is designed to empower manufacturers, engineers, and entrepreneurs to discover transformative solutions, forge supplier relationships, and establish cross-border partnerships that will define the future of manufacturing.

A landmark feature of this year’s event is the strategic partnership with the Malaysia Semiconductor Industry Association (MSIA). AUTOMEX Penang will co-host the prestigious Silicon Malaysia Forum (formerly the National E&E Forum), bringing together global leaders and innovators in the semiconductor sector. This strategic partnership will deepen industry integration and foster technological cooperation across the entire value chain.

“The semiconductor industry is the backbone of Penang’s economy and central to Malaysia’s competitiveness,” said Geonice Chong, Deputy Event Director of AUTOMEX Penang. “By co-hosting the Silicon Malaysia Forum at AUTOMEX Penang, we are creating a world-class platform that connects thought leaders, innovators, and investors across the E&E ecosystem. This will help Malaysia move further up the value chain into design, R&D, and advanced manufacturing, while reinforcing our place in the global semiconductor landscape.”

Penang is a vital hub for outsourced semiconductor assembly and test (OSAT) and home to many of the world’s leading technology companies. Its robust ecosystem of multinationals and SMEs contributes significantly to the global supply chain – underscoring its importance as Malaysia’s high-tech engine.

“For nearly three decades, METALTECH and AUTOMEX have championed innovation in Malaysia’s manufacturing sector. With AUTOMEX Penang 2025, we are taking this legacy forward by bringing the event to one of the nation’s most dynamic tech hubs. Our strategic partnership with MSIA positions us to significantly strengthen automation and semiconductor integration, driving Penang’s continued growth while solidifying Malaysia’s leadership position in the global digital economy,” added Geonice Chong.

A press conference was held on 28 August 2025 at the Deputy Chief Minister’s Office in Penang to officially announce the event’s launch. The press conference was attended by YB Jagdeep Singh Deo, Penang Deputy Chief Minister II, Dato’ Seri Wong Siew Hai, President, Malaysia Semiconductor Industry Association (MSIA), Ir. Johnson Tan, President, Malaysia Automation Technology Association (MATA), Geonice Chong, Deputy Event Director of AUTOMEX Penang and representatives from the Penang Convention & Exhibition Bureau (PCEB). Their presence underscores the strong industry-wide support and anticipation for AUTOMEX Penang 2025.

As Malaysia accelerates toward becoming a global Industry 4.0 powerhouse, AUTOMEX Penang 2025 will act as a catalyst for the next phase of industrial transformation in the northern region. By connecting local innovation with global opportunities, the event will position Malaysian manufacturing firmly at the cutting edge of technological advancement.

Seize the opportunity to be at the forefront of this industrial transformation. AUTOMEX Penang 2025 is your gateway to the latest technologies, key industry players, and invaluable business partnerships. Join us at AUTOMEX Penang 2025 from 4–6 November 2025 at the Setia SPICE Convention Centre.

Registration is now open. For more information or to register, please visit www.automex.com.my.

Notes to Editors:
About AUTOMEX Penang
AUTOMEX Penang is Malaysia’s premier exhibition for automation, robotics, and smart manufacturing. Building on a 14-year co-location with METALTECH in Kuala Lumpur, the event expands into Penang – Malaysia’s “Silicon Valley of the East” and a global hub for semiconductors and advanced manufacturing. The exhibition showcases the latest innovations in robotics, machine vision, artificial intelligence (AI), the Internet of Things (IoT), and sustainable manufacturing solutions – connecting global technology providers with multinational corporations and SMEs. By attending, industry professionals gain access to cutting-edge solutions, strategic partnerships, and insights from thought leaders. AUTOMEX Penang empowers manufacturers, engineers, and decision-makers to accelerate digital transformation, enhance competitiveness, and capture growth opportunities across the global Industry 4.0 value chain.

Medtronic executives to speak at upcoming investor conferences

By
Advertorial Desk
-

GALWAY, Ireland, Aug. 29, 2025 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the following investor conferences:

2025 Wells Fargo Healthcare Conference
Thursday, September 4, 2025, at 8:00 a.m. EDT (7:00 a.m. CDT)
Geoff Martha, Medtronic chairman and chief executive officer, and Thierry Piéton, Medtronic executive vice president and chief financial officer, will answer questions on the company.

Morgan Stanley 23rd Annual Global Healthcare Conference
Monday, September 8, 2025, at 4:50 p.m. EDT (3:50 p.m. CDT).
Thierry Piéton, Medtronic executive vice president and chief financial officer, will answer questions on the company.

2025 Deutsche Bank Healthcare Summit
Wednesday, September 10, 2025, at 12:00 p.m. EDT (11:00 a.m. CDT)
Greg Smith, Medtronic executive vice president, enterprise operations, will answer questions on the company.

BofA Global Research Global Healthcare Conference 2025
Wednesday, September 24, 2025 at 2:10 p.m. BST (8:10 a.m. CDT)
Thierry Piéton, Medtronic executive vice president and chief financial officer, will answer questions on the company.

A live webcast for each session will be available on the date and time of each of the conferences noted above by clicking on the Investors Events link at: http://investorrelations.medtronic.com. An archive session will be available on the same webpage later in the day.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts
Erika Winkels
Public Relations
+1-763-526-8478

Ryan Weispfenning
Investor Relations
+1-763-505-4626

 

Fosun International Hosts 2025 Interim Results Presentation, Reaffirms Confidence in Future Development Driven by Innovation and Globalization

By
Advertorial Desk
-

HONG KONG and SHANGHAI, Aug. 29, 2025 /PRNewswire/ — On the morning of 29 August, Fosun International held an interim results presentation in Shanghai, with attendees including Guo Guangchang, Chairman of Fosun International, Wang Qunbin, Co-Chairman of Fosun International, Chen Qiyu, Co-CEO of Fosun International, Xu Xiaoliang, Co-CEO of Fosun International, Gong Ping, CFO of Fosun International, along with numerous institutional investors and analysts.

Guo Guangchang, Chairman of Fosun International, highlighted that Fosun achieved significant breakthroughs across several business segments in the first half of 2025, particularly in the biopharmaceutical segment. Moving forward, Fosun will focus on deepening and thoroughly developing industries that it has established significant industry advantages, striving to achieve breakthroughs, accelerate growth, and ascend to the pinnacle within these mature sectors, securing a commanding global position.

In recent years, Fosun has continued to advance its business streamlining and core business-focused strategy. While divesting from a series of non-core assets, it has focused on high-growth core industries. Wang Qunbin, Co-Chairman of Fosun International, noted the importance of managing and reducing debt levels during the process of focused development. Building on ample cash flow and a reasonable debt ratio, Fosun is prioritizing growth in its core industries such as biopharmaceuticals, cultural tourism, and consumption, to strengthen its competitiveness.

Innovation is at the heart of Fosun’s ongoing strategy. In the first half of 2025, Fosun’s technology innovation strategy delivered breakthroughs, fostering a number of globally competitive innovations. Chen Qiyu, Co-CEO of Fosun International, emphasized that Fosun’s future development ultimately hinges on a strong focus on innovation. He noted that innovation must be built on a solid foundation, which involves strengthening and refining Fosun’s technology platforms. Building on these platforms, Fosun must also effectively leverage China’s local innovation capabilities. At the same time, Fosun should accelerate the development of two capabilities. The first is enhancing external collaboration and conversion capabilities to achieve efficient value realization. The second is expanding its capacity for global commercialization across international markets. This strategy, known as “Innovation + Globalization”, enables Fosun to unlock the full value of innovation through strong global commercial capabilities.

Regarding public concerns about innovative drug R&D, Guo Guangchang stated that Fosun’s current pipeline includes several innovative blockbuster products with significant global market potential, offering ample room for growth. Fosun’s pharmaceutical innovation extends beyond Henlius. It also includes Fosun Kite’s CAR-T therapy, along with innovative drugs from its established product divisions, all of which hold immense potential.

Guo Guangchang said, “I have been emphasizing to our team that we shouldn’t just sell off all our innovative drugs. Both licensing in and licensing out are important. Some products may command a high price if simply licensed out, but we are not in a rush. We should continue to advance our R&D to make these products the best in the world.”

As one of China’s largest private enterprises with the most extensive global business presence and operational capabilities, Fosun reached a new globalization milestone in the first half of 2025, with overseas revenue now accounting for 53% of the Group’s total revenue. Xu Xiaoliang, Co-CEO of Fosun International, said that Fosun has evolved from “combining China’s growth momentum with global resources” to “integrating China’s capabilities with global assets”. These capabilities are reflected in several areas: global R&D and business development, global investment, promoting Chinese culture abroad, and global operations. Fosun will continue to focus on its strategy, address challenges through development, and adopt a long-term approach to navigate economic cycles, creating greater value for shareholders and society.

Regarding the Group’s financial results in the first half of the year, Gong Ping, CFO of Fosun International, stated that Fosun’s financial strategy continues to evolve around strategic focus and steady development. In implementing this strategy, the Group has been disciplined in prioritizing its industries, concentrating resources on businesses with the potential to become industry leaders, and steadily advancing asset-light operations. Looking ahead, Fosun aims to gradually increase the proportion of overseas revenue while reducing interest-bearing debt to around RMB60 billion or less. At the same time, the Group strives to achieve RMB10 billion in both industrial operation profit and profit attributable to owners of the parent. Building on this, Fosun plans to gradually raise its dividend payout ratio and steadily raise its credit rating, ultimately achieving investment-grade rating.

In the first half of 2025, Fosun actively captured macroeconomic trends, maintained a clear strategic focus, and leveraged its strong capabilities in innovation and globalization to drive steady business development. During the Reporting Period, the Group’s total revenue reached RMB87.28 billion, industrial operation profit amounted to RMB3.15 billion, and profit attributable to owners of the parent reached RMB661.2 million. The four core subsidiaries – Fosun Pharma, Yuyuan, Fosun Insurance Portugal and Fosun Tourism Group – achieved a total revenue of RMB63.61 billion in the first half of 2025, accounting for 73% of the Group’s total revenue. As at the end of the Reporting Period, the total debt to total capital ratio stood at 53%, with debt ratio remaining at a healthy level. In May 2025, the international credit rating agency S&P affirmed Fosun’s credit metrics and maintained its rating outlook as “Stable”.

Lifezoom Updates: Refining Efficient Light Therapy Products Based on Customer Insights

By
Advertorial Desk
-

NEW YORK, Aug. 29, 2025 /PRNewswire/ — Since its launch, Lifezoom‘s light therapy devices have steadily become a promising contender in the industry. However, users’ feedback revealed that the original single blue light mode is primarily suitable for short-term use, which highlights the limited benefits of blue light, with most customers calling for higher efficiency at specific wavelengths.

As Lifezoom‘s CEO mentioned, “User feedback is our most important guide. In this instance, we acted quickly to enhance the red light wand, reflecting Lifezoom’s core philosophy of putting user needs at the center.” In response to customers’ needs, an update of the red light therapy wand will be launched. The following sections will provide detailed information about Lifezoom’s upcoming product updates, as well as the products that have also been developed based on customer feedback.

The Handheld Red Light Wand and the Veyra Series from Lifezoom differ in product size, but both offer flexible and practical functionality, providing users with effective, targeted treatment for localized areas and supporting a variety of health needs, including wound healing and relief from muscle soreness.
The Handheld Red Light Wand and the Veyra Series from Lifezoom differ in product size, but both offer flexible and practical functionality, providing users with effective, targeted treatment for localized areas and supporting a variety of health needs, including wound healing and relief from muscle soreness.

Red Light Therapy Wand: Enhanced Through User Feedback

The previous version of the Handheld Light Therapy Wand by Lifezoom proved to be an excellent product for those seeking improvement in acute skin conditions, such as acne. Yet, many users also requested the addition of anti-aging and tissue-repair effects alongside anti-inflammatory benefits. The idea of the red light therapy wand originated from user feedback on the previous device iteration.

After carefully reviewing and summarizing customer feedback, Lifezoom’s decision-makers, together with R&D engineers, have planned to replace the original 460 nm blue-only setting with a combined red and near-infrared mode. This change was made based on customer feedback: the new red + near-infrared protocol will increase tissue penetration and can efficiently promote rapid wound healing and tissue repair. [1]

Precision Care: Key Features of the Red Light Therapy Wand

The new Red Light Therapy Wand by Lifezoom will be optimized to further enhance its therapeutic efficacy by utilizing two wavelengths for treatment:

  • Red light (660nm). Mainly used to promote superficial tissue repair, healing, and shows significant anti-aging effects.[2]
  • Near-infrared light (850nm). Light of this spectrum can penetrate biological objects much deeper than other parts of the spectrum, thereby improving deep-tissue healing and repair.[1]

Veyra Curved Light Series: Efficient Healing at Home

The Veyra Curved Light Series is a tangible demonstration of Lifezoom’s swift response — and more importantly, of its proactive attention to users’ demands. The device delivers targeted therapeutic effects for localized areas, similar to those of the Red Light Therapy Wand, but it is more effective, faster, and suitable for much larger areas of skin. Featuring 96 high-power LEDs mounted in a curved frame, the Veyra Curved Light Series can be placed anywhere in the house, or applied to specific parts of the body (e.g., the belly). The following light spectrum is responsible for its healing effects:

Thanks to its ergonomic design and set of stands, the Veyra Curved Light Series device can be placed near a bed, on a work desk, or on a couch. As a result, users have an excellent opportunity to incorporate red light therapy into their daily routine, without needing to focus excessively on a single session. The user friendly interface, the one button power, and the timer adjustments make the device easy to start and operate. At the same time, these features allow users to continue their routine tasks while enjoying a full scale red light therapy session.

Veyra Curved Light Series devices have proven to be a great additional solution for those who struggle with chronic pain, and they can also be handy for sports enthusiasts and for those seeking to relieve muscle pain. Sleep-deprived users can also benefit from red light therapy, which may help reduce anxiety and negative emotions associated with lack of sleep.[3] In general, Veyra Curved Light Series devices will be a great, easy-to-use, and effective solution for all those who struggle to maintain a healthy lifestyle at home.

To learn more about the detailed specifications of Lifezoom’s products and stay updated on future releases, please visit the official Lifezoom website or the Lifezoom store on Amazon.

Aspiration of Lifezoom: Built for Becoming

The Veyra Series and the Red Light Wand differ in specifications and modes of use, both embody the same principle of high-performance flexibility within their categories. Unlike the rigidity of mainstream red light products, Lifezoom demonstrates brand vitality through its fluid, adaptive design. This vitality comes not only from the dedication of its R&D team but also from its attentiveness to customer feedback—addressing current needs while uncovering new and unspoken demands.

By transforming daily living into a gentle ritual of care, Lifezoom ensures that clinical-grade insights are no longer complex, and wellness tools offer support rather than burden. In this vision, Lifezoom is built for becoming a brand that evolves with its users, enabling them to continuously grow into the healthiest and most empowered version of themselves.

Media Contact: Joey, marketing@lifezoom.tech

References:

  1. Balbinot, G. S., et al. (2021). Photobiomodulation, Cells of Connective Tissue and Repair. MDPI. https://www.mdpi.com/2304-6732/9/9
  2. Zhang, G., et al. (2015). Effect of 660 nm Light‐Emitting Diode on the Wound Healing in Fibroblast-Like Cell Lines. BioMed Research International. https://doi.org/10.1155/2015/916838 
  3. Leal Junior, E. C., et al. (2015). “Effect of 660 nm Light-Emitting Diode on the Wound Healing in Fibroblast-Like Cell Lines.” BioMed Research International. https://pmc.ncbi.nlm.nih.gov/articles/PMC4299734
  4. Pan, R., Zhang, G., Deng, F., Lin, W., & Pan, J. (2023). Effects of red light on sleep and mood in healthy subjects and individuals with insomnia disorder. Frontiers in Psychiatry, 14, Article 1200350. https://doi.org/10.3389/fpsyt.2023.1200350

 

Wesley Methodist School Celebrates Unity, Patriotism, and Diversity in Conjunction with National Day

By
Advertorial Desk
-

Book Launch: Voices of Patriotism and Unity – The Recipe for Malaysia’s Success


KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 29 August 2025 – Wesley Methodist School launches a special commemorative book set, Anthology of Poems – Voices of Patriotism and Unity – The Recipe for Malaysia’s Success, a collection written by its teachers and students to honour the spirit of Malaysia.

The Official Book Launch by the VIPs
The Official Book Launch by the VIPs

The launch, officiated by YB Wong Kah Woh, Deputy Minister of Education, marks not only the unveiling of these inspiring works but also the celebration of a nation built on inclusivity, diversity, and unbreakable unity. YB Wong, whose message is also featured in the book, graced the occasion with his presence, underlining the significance of patriotism in shaping the future of Malaysia.

In his address, YB Wong also highlighted the importance of a holistic curriculum that develops well-rounded students. He emphasised that education should extend beyond academic achievement to include patriotism, digital and financial literacy, social-emotional learning, and entrepreneurship.

In conjunction with the National Day celebration, Wesley Methodist Schools across Peninsular Malaysia organised a series of activities to foster patriotism and unity among students and teachers:

  • Wesley Methodist School Penang (International): A Patriotic Unity Run was held symbolising shared pride and patriotism among the students and their teachers.
  • Wesley Methodist School Kuala Lumpur (Private): Students participated in choral speaking, sajak recitation, patriotic singing, and came dressed in traditional attire to showcase Malaysia’s cultural richness.
  • Wesley Methodist School Klang (Private): The school highlighted cultural inclusion through song and dance performances, traditional games, and team activities such as coconut bowling, encouraging camaraderie and festive spirit.
Penang school commemorated Malaysia’s National Day by uniting students and teachers in a spirit of togetherness and patriotism.
Penang school commemorated Malaysia’s National Day by uniting students and teachers in a spirit of togetherness and patriotism.
KL school students lit up the stage with a vibrant Merdeka performance, celebrating unity and culture
KL school students lit up the stage with a vibrant Merdeka performance, celebrating unity and culture

These meaningful activities complemented the book launch, reflecting Wesley Methodist Schools’ ongoing commitment to nurturing not only academic growth but also national identity, values of inclusivity, and love for the country.

For more information about the books or Wesley Methodist School, please contact:
+603-7956 5310 / +603-7957 7746.

Hashtag: #Merdeka2025 #StrongerTogetherMY #UnityInDiversity #FaithHopeUnity #BuildingTheNationTogether #CelebratingMalaysia #VoicesOfUnity #HarmonyAndHope #PatriotismInAction #BanggaJadiAnakMalaysia #CintaTanahAir

The issuer is solely responsible for the content of this announcement.

Wesley Methodist School

Wesley Methodist School (WMS) provides a well-rounded, character-driven education that nurtures the mind, body, and spirit. Rooted in Christian values, our holistic approach combines academic excellence with strong character formation, instilling confidence, resilience, and integrity in every student.

Guided by our core values of God-centredness, Integrity, Respect for Life, and Excellence with Humility, we prepare students to thrive in life and make a positive impact on society.

1...2,6462,6472,648...6,535Page 2,647 of 6,535